Skip to content
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.
Company
Companies

KAINOS Laboratories

カイノス

4556 · TSE · Pharmaceutical

Financials Company only

Revenue¥5.31bn+4.9% year on yearCompany only · FY3/25

Ordinary profit¥828m−10.8% year on yearCompany only · FY3/25

Dividend per share¥35.00FY3/25

Performance over time

Revenue
¥4.26bnFY3/21
¥4.61bnFY3/22
¥4.92bnFY3/23
¥5.06bnFY3/24
¥5.31bnFY3/25
Ordinary profit
¥654mFY3/21
¥778mFY3/22
¥854mFY3/23
¥929mFY3/24
¥828mFY3/25
Op. cash flow
¥591mFY3/21
¥604mFY3/22
¥545mFY3/23
¥431mFY3/24
¥705mFY3/25

People & pay

Employees157 peopleFY3/25

Average salary¥7.22mFY3/25

Average salary is for the parent company's own employees (non-consolidated), as Japanese annual reports disclose it.

Five-year history
Five-year history
Fiscal yearRevenueOrdinary profitEPSDividendTotal assetsNet assetsOp. cash flow
FY3/25¥5.31bn+4.9% year on year¥828m¥152.06¥35.00¥8.79bn¥6.78bn¥705m
FY3/24¥5.06bn+2.7% year on year¥929m¥152.26¥32.00¥8.59bn¥6.27bn¥431m
FY3/23¥4.92bn+6.7% year on year¥854m¥136.13¥25.00¥8.12bn¥5.67bn¥545m
FY3/22¥4.61bn+8.4% year on year¥778m¥126.39¥25.00¥7.57bn¥5.20bn¥604m
FY3/21¥4.26bn¥654m¥100.63¥15.00¥6.96bn¥4.66bn¥591m

Per-share figures are as each report states them: a share split is restated only for the year before it, and dividends are as paid.

Figures from annual report S100W0MS · Japan GAAP. Each figure's years come from one report's five-year summary.

Tender offers

Recent offers involving this company.

1 offer · data through

Tender offers
RoleOfferorPrice / shareDeadlineTarget opinionFiling
TargetFlowers株式会社¥2,285Post-offer stake 94.74%Minimum shares: 1,990,000SucceededSupportRecommends tenderingFiled · Filing 1 S100XK0U Filing 2 S100XP3J
+2 more filingsFiling 3 S100XK20 Filing 4 S100XUGA

Cross-holdings

Strategic shareholdings and sales, by fiscal year.

5 fiscal years · data through

Balance-sheet value
¥122mFY3/21
¥124mFY3/22
¥138mFY3/23
¥189mFY3/24
¥232mFY3/25

Balance-sheet value is the reporting company's own listed holdings (its largest holding subsidiary's where marked), carried at market value; the percentage divides it by consolidated net assets in the same annual report.

Cross-holdings
Fiscal year endHoldings (issuers)Balance-sheet value% of consolidated net assetsIssues cutSale proceedsFiling
31 Mar 20256¥232m———Filed  — filing S100W0MS
Show 4 more fiscal years (5 total)
Cross-holdings
Fiscal year endHoldings (issuers)Balance-sheet value% of consolidated net assetsIssues cutSale proceedsFiling
31 Mar 20246¥189m———Filed  — filing S100TPAC
31 Mar 20236¥138m———Filed  — filing S100R22U
31 Mar 20226¥124m———Filed  — filing S100O9SP
31 Mar 20216¥122m———Filed  — filing S100LKLF